Profile data is unavailable for this security.
About the company
ProKidney Corp. is a clinical-stage biotechnology company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patient’s diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patient’s own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participant’s own kidney tissue. Its patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. It is conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease (DKD).
- Revenue in USD (TTM)0.00
- Net income in USD-45.61m
- Incorporated2021
- Employees163.00
- LocationProKidney Corp2000 Frontis Plaza Blvd., Suite 250WINSTON-SALEM 27103United StatesUSA
- Phone+1 (336) 999-7028
- Websitehttps://prokidney.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Terns Pharmaceuticals Inc | 0.00 | -88.07m | 481.92m | 66.00 | -- | 1.33 | -- | -- | -1.18 | -1.18 | 0.00 | 4.29 | 0.00 | -- | -- | 0.00 | -27.10 | -41.34 | -28.12 | -45.70 | -- | -- | -- | -31,010.30 | -- | -- | 0.00 | -- | -- | -- | -49.49 | -- | -26.60 | -- |
| GH Research PLC | -100.00bn | -100.00bn | 500.51m | 49.00 | -- | 2.64 | -- | -- | -- | -- | -- | 3.64 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0039 | -- | -- | -- | -58.47 | -- | -- | -- |
| ProKidney Corp | 0.00 | -45.61m | 504.03m | 163.00 | -- | -- | -- | -- | -0.5541 | -0.5541 | 0.00 | -3.36 | 0.00 | -- | -- | 0.00 | -29.48 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0003 | -- | -- | -- | 67.17 | -- | -- | -- |
| SS Innovations International Inc | 16.39m | -27.82m | 512.22m | 239.00 | -- | 36.90 | -- | 31.25 | -0.1638 | -0.1638 | 0.0962 | 0.0813 | 0.5298 | 1.67 | 4.22 | 68,573.09 | -89.92 | -161.38 | -160.65 | -449.76 | 31.96 | -79.79 | -169.74 | -495.77 | 0.9225 | -39.81 | 0.4746 | -- | -- | -- | -846.31 | -- | 159.31 | -- |
| Monte Rosa Therapeutics Inc | 14.98m | -119.39m | 513.00m | 103.00 | -- | 2.49 | -- | 34.26 | -1.83 | -1.83 | 0.2215 | 3.35 | 0.0528 | -- | 33.69 | 112,594.00 | -42.10 | -- | -47.48 | -- | -- | -- | -797.26 | -- | -- | -- | 0.00 | -- | -- | -- | -24.75 | -- | -- | -- |
| Alumis Inc | 0.00 | -238.77m | 513.57m | 145.00 | -- | 1.47 | -- | -- | -4.52 | -4.52 | 0.00 | 6.40 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -38.47 | -- | -- | -- |
| Third Harmonic Bio Inc | 0.00 | -39.20m | 515.92m | 51.00 | -- | 1.74 | -- | -- | -0.9694 | -0.9694 | 0.00 | 6.59 | 0.00 | -- | -- | 0.00 | -13.36 | -- | -13.66 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.32 | -- | -- | -- |
| Mind Medicine (MindMed) Inc | 0.00 | -97.80m | 519.92m | 57.00 | -- | 2.21 | -- | -- | -1.99 | -1.99 | 0.00 | 3.21 | 0.00 | -- | -- | 0.00 | -42.40 | -- | -49.28 | -- | -- | -- | -- | -- | -- | -- | 0.0849 | -- | -- | -- | -68.55 | -- | -- | -- |
| Sana Biotechnology Inc | 0.00 | -305.81m | 524.68m | 328.00 | -- | 1.79 | -- | -- | -1.41 | -1.41 | 0.00 | 1.31 | 0.00 | -- | -- | 0.00 | -51.36 | -38.99 | -56.78 | -42.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.11 | -- | 112.71 | -- |
| Astria Therapeutics Inc | 0.00 | -100.04m | 527.01m | 59.00 | -- | 2.14 | -- | -- | -2.09 | -2.09 | 0.00 | 6.05 | 0.00 | -- | -- | 0.00 | -36.02 | -64.48 | -37.72 | -68.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.62 | -- | -- | -- |
| IGM Biosciences Inc | 2.92m | -219.84m | 527.34m | 198.00 | -- | 6.69 | -- | 180.72 | -3.65 | -3.65 | 0.0484 | 1.33 | 0.0075 | -- | -- | 13,026.79 | -56.45 | -44.66 | -63.54 | -48.20 | -- | -- | -7,534.03 | -23,668.96 | -- | -- | 0.00 | -- | 99.25 | -- | -11.45 | -- | 73.48 | -- |
| Organogenesis Holdings Inc | 455.04m | -7.38m | 532.95m | 862.00 | -- | 1.91 | 56.65 | 1.17 | -0.0567 | -0.0567 | 3.43 | 2.10 | 1.00 | 4.09 | 4.78 | 527,886.30 | -1.62 | 5.46 | -1.97 | 6.90 | 75.29 | 74.94 | -1.62 | 4.81 | 2.74 | 6.56 | 0.1875 | 0.00 | -3.94 | 17.49 | -68.16 | -- | 67.34 | -- |
| Ironwood Pharmaceuticals, Inc. | 378.42m | -2.46m | 534.49m | 267.00 | -- | -- | -- | 1.41 | -0.016 | -0.016 | 2.39 | -1.95 | 0.8284 | -- | 3.77 | 1,417,296.00 | -0.6832 | -4.54 | -1.07 | -5.20 | -- | -- | -0.8248 | -7.81 | -- | 3.88 | 2.08 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
Data as of Nov 22 2024. Currency figures normalised to ProKidney Corp's reporting currency: US Dollar USD
39.47%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Morgan Stanley Investment Management, Inc.as of 30 Sep 2024 | 13.91m | 11.03% |
| Suvretta Capital Management LLCas of 30 Sep 2024 | 12.34m | 9.79% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 5.98m | 4.74% |
| GBM Administradora de Activos, SA de CV SOSIas of 30 Aug 2024 | 5.18m | 4.11% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 5.04m | 4.00% |
| Geode Capital Management LLCas of 30 Sep 2024 | 2.20m | 1.75% |
| Bleichroeder LPas of 30 Sep 2024 | 1.85m | 1.46% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 1.43m | 1.13% |
| Brown University Investment Officeas of 30 Sep 2024 | 1.00m | 0.79% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2024 | 829.70k | 0.66% |
More ▼
Data from 30 Aug 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
